1. A specific method is described for the measurement of angiotensin I converting enzyme activity in plasma with 1251-labelled angiotensin I used as substrate.
1. A specific method is described for the measurement of angiotensin I converting enzyme activity in plasma with 1251-labelled angiotensin I used as substrate.
2. Converting enzyme activity in plasma from fifteen normal subjects, eleven patients with sarcoidosis, twelve patients with chronic obstructive pulmonary disease and three patients with shock lung was assayed by this technique.
3. Patients with sarcoidosis had increased plasma converting enzyme activity whether or not they were receiving steroid therapy. 4. Patients with chronic obstructive pulmonary disease and shock lung had decreased plasma converting enzyme activity, but extent of conversion did not correlate with the severity of the lung disease.
5. Converting enzyme activity in normal plasma could be completely inhibited by addition of exogenous angiotensin I in 05-25 x lo7 times physiological concentration. Twice as much exogenous angiotensin I was needed to inhibit conversion completely in plasma from patients with sarcoidosis; one tenth as much in chronic obstructive pulmonary disease. These results indicate that plasma has a high capacity for angiotensin I conversion even in patients with pulmonary parenchymal disease.
6. Results suggest that plasma converting enzyme activity may be a reflection of pulmonary conversion and can be altered by pulmonary disease.
Introduction
Since large amounts of angiotensin I converting enzyme are found in plasma and in a number of organs and since angiotensin I infused in supraphysiological concentration is rapidly converted into angiotensin I1 in viuo, the conversion step has not generally been regarded as ratelimiting for angiotensin I1 production. Accordingly, relatively little attention has been given to the regulation of converting enzyme activity in vivo. Recent studies by non-specific analytical techniques have suggested that converting enzyme activity can be altered in the normal animal by changes in oxygenation (Molteni, Zakheim, Mullis & Mattioli, 1974) and in the isolated perfused dog lung by changes in pulmonary haemodynamics (Fanburg & Glazier, 1973) . In addition, abnormalities in plasma converting enzyme activity have been reported in patients with sarcoidosis and chronic lung disease of other aetiologies (Lieberman, 1975; Oparil, Low & Koerner, 1975; Siverstein, Friedland, Lyons & Kitt, 1975b) . To test the hypothesis that plasma converting enzyme activity is altered in patients with sarcoidosis and other kinds of lung disease and therefore that plasma conversion may parallel intrapulmonary conversion, specific methods were developed for quantifying converting enzyme activity in human plasma with angiotensin I used as substrate. Plasma from patients with sarcoidosis, chronic obstructive pulmonary disease or 'shock' lung and plasma from normal volunteer subjects was assayed for converting enzyme activity.
Methods
Samples of blood (10 ml) were drawn from the antecubital veins into iced glass tubes containing heparin (143 USP units). The plasma was separated within minutes at 4°C by centrifugation. A portion (1 ml) of each plasma sample was diluted (1:3*5) with Trislacetate buffer (0.1 mol/l, pH 7.4) containing NaCl(O.1 mol/l). Because converting enzyme has a higher affinity than angiotensinases for the substrate angiotensin, dilution of plasma favours conversion over breakdown. 251-labelled angiotensin I (5 x lo7 c.p.m.; 30.0 pmol) (New England Nuclear, Boston, Mass., U.S.A.) was added to 4.5 ml of diluted plasma. The mixture was incubated at 37°C and aliquots (250 pl) were removed at 0, 2.5, 5, 7.5, 10, 15 and 30 min. A portion (50 pl) was immediately spotted on Whatman 3MM paper and subjected to electrophoresis (Savant Co., Hicksville, N.Y., U.S.A.) at 4000 V for 1 h in pyridinelacetate buffer, pH 3.55, for identification and quantification of angiotensin I, angiotensin I1 and their metabolites.
The paper was dried, cut into 1 cm strips, and the radioactivity was counted in a gamma counter (Nuclear Chicago, Desplaines, Ill., U.S.A.). The remaining 200 pl was treated with 8-hydroxyquinoline (3.4 mmol/l final concentration) to inhibit plasma converting enzyme and angiotensinases. These samples were subjected to column chromatography as an independent means of identifying and quantifying the angiotensins and their metabolic products. The stored samples were thawed and passed through a 0.9 cmx100 cm column of DEAE-Sephadex A-25, which was developed with sodium phosphate buffer (0.1 mol/l, pH 7.4) at room temperature. A sample (1 ml) of each 3 ml fraction of column eluate was counted for radioactivity. Generated angiotensin I1 was distinguished from angiotensin I and from the products of other circulating enzymes by comparison with standard peptides, which had been prepared by enzymatic digestion of 1251-labelled angiotensin I and 1251-labelled angiotensin 11. The mono-iodinated angiotensins were incubated with trypsin, chymotrypsin or leucine aminopeptidase (Worthington Biochemal Corp., Freehold, N.J., U.S.A.) under conditions in which the reactions went to completion (Oparil, Koerner, Tregear, Barnes & Haber, 1973) . Peptide fragments of known sequence generated by these procedures were subjected to high-voltage paper electrophoresis and column chromatography on DEAE-Sephadex. When analysed by both techniques, all of the small peptide fragments occupied positions distinguishable from one another and from angiotensin I and 11. The only fragments encountered after incubation of human plasma were the labelled product of chymotryptic digestion, which presumably consisted of the (1-4) sequence, and mono-iodinated tyrosine.
The effect of substrate inhibition was assessed by adding graded amounts of unlabelled angiotensin I to tracer quantities of 1251-labelled angiotensin I and incubating with diluted plasma, as described above. Converting enzyme was considered to be completely inhibited by substrate when no conversion of 1251-labelled angiotensin I was detected over a 5 min incubation period. Plasma samples from one normal subject, one patient with chronic obstructive lung disease and two patients with sarcoidosis were examined.
Blood samples from a total of fifteen normal subjects (nine male and six female), eleven patients with sarcoidosis (seven male and four female), twelve patients with chronic obstructive lung disease (six male and six female) and three male patients with 'shock' lung were assayed for converting enzyme activity. Converting enzyme activity was assessed by computing percentage conversion [(AII/AI + AII)
x 1001, for each time-point and plotting percentage conversion against time. Sarcoidosis was diagnosed from a typical chest X-ray picture (bilateral reticular infiltrates with or without hilar adenopathy) in the absence of evidence for tuberculous or fungal infection by skin test and culture. No patient had evidence of pulmonary or extrapulmonary malignancy. The arterial Po, of all patients with sarcoidosis was > 9.5 kPa (>70 mmHg) on room air. Pulmonary function tests were normal or showed only mild restrictive abnormalities. In seven of eleven cases, non-caseating granulomata were found on liver or lymph node biopsy. Of the four patients from whom biopsies were not obtained, one had uveitis and skin lesions typical of sarcoidosis and three had shown resolution of pulmonary infiltrates and hilar adenopathy with steroid therapy. The Kveim test was not used because of the difficulty in obtaining high-quality antigen and because of the high incidence of false negatives.
Chronic obstructive lung disease was diagnosed on clinical grounds and by pulmonary function testing. All patients had a chronic cough and progressive exertional dyspnoea without evidence of cardiac disease. Chest X-ray films showed no evidence of infiltration, mass lesions or hilar lymph adenopathy. All patients had moderately severe to severe obstructive abnormalities on pulmonary function tests. The patients with 'shock' lung had all developed progressive intrapulmonary arteriovenous shunting after a period of hypotension and decreased cardiac output. None was able to maintain an arterial Po2>8 kPa (>60 mmHg) even with assisted ventilation via an endotracheal tube; none survived.
Statistical analyses were performed by comparing results of incubation of normal and patient plasma for each time of sampling by the unpaired Student's t-test. Results for grouped data are presented as the mean values k SEM.
Results
Results from a representative experiment with a normal subject, a sarcoidosis patient and a patient with chronic lung disease are summarized in Fig. 1 .
Conversion of angiotensin I into I1 was both more extensive and more rapid in the sarcoidosis patient than normal; conversion was less extensive and slower in the patient with chronic obstructive lung disease than normal. The rate of generation of tyrosine and the (1-4) peptide, metabolic products of angiotensin I and 11, appeared to be greater in the sarcoidosis patient than in the normal or in the patient with chronic lung disease. In all individuals, the inactive metabolites accounted for a substantial proportion (>25%) of total radioactivity counts only after 10 min of incubation. Results obtained with column chromatography on DEAE-Sephadex A-25 confirmed those obtained with paper electrophoresis.
The data for normal subjects and patients with sarcoidosis or chronic obstructive lung disease studied are in Fig. 2 . Mean percentage conversion for patients with sarcoidosis was significantly (P<O.Ol to <0.001) greater than normal at all time-points except at 0 and 30; mean percentage conversion for patients with chronic obstructive lung disease was significantly less than normal only at 2.5 (P<O.005) and 7.5 (Pc0.05) min. Steroid treatment of sarcoidosis did not appear to alter plasma converting enzyme activity. Both treated and untreated patients are included in Fig. 2 . The rate of conversion was more variable in chronic obstructive lung disease than in either sarcoidosis or the normal population. Mean percentage conversions at 7.5, 10 and 15 min for patients with chronic obstructive lung disease were 36 k 5% (SEM), 48 +7% and 65+9% respectively; for patients with sarcoidosis, 71 & 3 %, 86 k 2% and 98 2 1 %; for normal subjects, 48 k 3 %, 58 k 2% and 72 k 2%. The greater variability in the obstructive lung disease group may be attributed to heterogeneity in aetiology and severity of the lung disease. The three patients with shock lung had less converting enzyme activity than either normal subjects or patients with chronic lung disease. Mean percentage conversions at 7.5, 10 and 15 min were 22k7%, 31 +5% and 29 k 6%. These are significantly (P c 0.001) below normal for each time-point. Table 1 summarizes the results of experiments in which graded amounts of unlabelled angiotensin I were added to the incubation mixture in order to assess the capacity of the system for conversion. The patient with obstructive lung disease required less (50 nmol/ml vs. 500 nmol/ml) of angiotensin I than the normal subject to inhibit conversion completely; the two sarcoidosis patients required twice as much unlabelled angiotensin I as the normal subject. These results indicate that the plasma from sarcoidosis patients has an increased capacity for conversion of angiotensin I into I1 and that the plasma from patients with obstructive lung disease has a decreased capacity for conversion.
In normal plasma the rate of conversion of lz5I-labelled angiotensin I was completely inhibited by unlabelled angiotensin I only at concentrations 10-25 x lo6 times those achieved physiologically (assuming a normal circulating angiotensin I concentration of 10-90 fmol/ml; Waite, 1973) . The very high capacity of plasma converting enzyme can be attributed to a high concentration of enzyme in plasma, to rapid turnover of angiotensin I at the active site of the enzyme or to both. The present experiments do not allow us to distinguish between the three possibilities.
Discussion
Several reports have suggested that alterations in angiotensin I conversion occur in pulmonary disease and when abnormalities in pulmonary function are experimentally induced. Molteni et al. (1974) showed that serum and lung converting enzyme activity (as assessed by the spectrophotometric method of Cushman & Cheung, 1971 ) and renal renin content were elevated in mice within 2 weeks of Manipulation of pulmonary vascular surface area and mean transit time through the pulmonary capillary bed by changing pulmonary venous pressure altered conversion of injected angiotensin I in the isolated perfused dog lung (Fanburg & Glazier, 1973) . Conversion increased with prolongation of transit time, which caused a lengthening of exposure of substrate to enzyme. These observations are compatible with the hypothesis that alterations in pulmonary function may have regulatory effects on the renin-angiotensin system through the activity of the angiotensin I converting enzyme. Depressed plasma converting enzyme activity has been reported in patients with several kinds of pulmonary disease, including chronic obstructive pulmonary disease, tuberculosis, carcinoma and cystic fibrosis (Lieberman, 1974; Oparil, Low & Koerner, 1975) . The observed depression of con-verting enzyme activity did not correlate with the severity of the lung disease. In contrast, converting enzyme activity was elevated in plasma (Lieberman, 1975; Oparil, Low & Koerner, 1975; Silverstein, Friedland, Lyons & Kitt, 1975b) and lymph node extracts (Silverstein, Friedland, Lyons & Gourin, 1975a) of patients with sarcoidosis. These observations suggest that plasma converting enzyme activity may be a reflection of the concentration and/or activity of the pulmonary converting enzyme.
Further evidence that converting enzyme activity is increased in sarcoidosis and depressed in chronic obstructive pulmonary disease was provided by those experiments of the current study in which the rate of conversion of '251-labelled angiotensin I was slowed by addition of large excesses of unlabelled angiotensin I. More unlabelled substrate was required to slow conversion in plasma from patients with sarcoidosis than in normal plasma; less unlabelled substrate was required to slow conversion in plasma from patients with chronic obstructive pulmonary disease than in normal plasma. Inhibition (or saturation) of converting enzyme was probably due to excess of substrate rather than the accumulation of split products of hydrolytic enzymes, since, at the incubation time chosen, angiotensinase activity was not detectable and [(AII/AI+AII) x 1001 was ~2 5 % .
The results suggest that either there are increased amounts of circulating plasma converting enzyme in patients with sarcoidosis and decreased amounts of enzyme in patients with chronic obstructive pulmonary disease or that the enzyme in sarcoidosis is more active and in obstructive pulmonary disease is less active than in the normal subject. These data do not permit us to distinguish between the two possibilities.
The site@) of origin of plasma converting enzyme remain obscure. Attempts to establish the identity of converting enzyme from plasma and from various organs have been made by comparing kinetics, substrate specificity and antigenic properties of purified preparations. Antibody raised to purified renal converting enzyme cross-reacted with both homologous lung and plasma enzyme (Oshima, Gecse & Erdos, 1974) . This observation does not allow differentiation among the various organ beds as sites of origin of converting enzyme. It is likely, however, that since pulmonary converting enzyme is found in greatest concentration and in most intimate proximity to circulating blood, the lung is the most important source of the plasma enzyme.
The studies of Lieberman (1975) and Silverstein et al. (1975a, b) utilized a spectrophotometric method in which the rate of release of free hippuric acid from an artificial substrate, hippurylhistidylleucine, was quantified. Since proteolytic enzymes from plasma and lymphoid tissue other than angiotensin I converting enzyme may cleave the artificial substrate, this method is not highly specific when used in unpurified plasma or tissue extracts. Use of the labelled natural substrate for the enzyme provides a more specific assay procedure for converting enzyme. The accelerated rate of appearance of tyrosineand the (1-4) peptidein plasma from patients with sarcoidosis suggests that the activities of proteolytic enzymes which act as angiotensinases as well as converting enzyme are elevatedin that disease. The source of theenzymes and their rolein the pathogenesis of the sarcoidosis are obscure. Nevertheless, it has been suggested (Lieberman, 1975) that the measurement of plasma converting enzyme may be useful in the diagnosis of sarcoidosis and in the assessment of its severity. In our study and that of Silverstein et al. (1975a) steroid treatment of sarcoidosis did not alter the elevated plasma converting enzyme activity. Further data will be needed before the value of plasma converting enzyme assay in the diagnosis and management of chronic lung disease can be assessed.
The abnormalities in converting enzyme activity observed in lung disease have not been associated with alterations in circulating angiotensin I1 concentration or renin activity or in cardiovascular homeostasis, but these relationships have not yet been rigorously investigated. The technique for measurement of plasma converting enzyme activity described here is rapid and specific and may be useful in the characterization of the regulatory role of converting enzyme in the renin-angiotensin system and cardiovascular homeostasis.
